Experience of tribudate (trimebutine) usage for prevention of postoperative nausea and vomiting syndrome in abdominal surgery
The study of the most probable development of the postoperative nausea and vomiting syndrome was performed in40 patients. These were young women I-II ASA, which laparoscopic surgery of ovarian cysts, infertility, endometrial hyperplasia was performed. All of the patients were underwent general anesthesia of the same type. After obtaining in- formed consent from patients, they were randomly divided into two groups by 20 persons each. 50 mg (5 ml) of tribudate was administered intravenously in a 20 minutes before the start of the operation to a experimental group, and postoper- ative 200 mg orally tribudate was administered twice with an interval of 6 hours. To a control group, on the above algo- rithm, placebo (0,9% 5 ml NaCl) was introduced instead tribudate. The postoperative nausea and vomiting syndrome in the control group was appeared in 11 (55%) patients, and in the experimental group - in 6 (35%) patients. Tribudatecompared with placebo in 1,8 times prevented the emergence of postoperative nausea and vomiting syndrome.